Sensorion, a biotech company specializing in the treatment of inner ear diseases, has appointed Nawal Ouzren as the Company’s new CEO.
Nawal Ouzren, who has fifteen years of experience in operational and strategic management within the pharmaceutical industry, will replace Laurent Nguyen who will support Ouzren as advisor to the CEO during the next six months.
Laurent Nguyen says: “I am proud of the Sensorion team that has, in five years, enabled a research company to be transformed into a structured biotech listed on the Alternext Paris market. This successful transformation has produced a unique screening platform in the high-potential inner-ear diseases sector and its two first drug candidates, SENS-111 in phase 2 and SENS-401 in phase 1. I think of all the patients suffering from vertigo, hearing loss or tinnitus and am delighted that Nawal will be able to continue the strategy implemented since our IPO, develop structural partnerships and continue to develop drug candidates and take them to market.”